Document Detail


Treatment of prolymphocytic leukemia with cladribine.
MedLine Citation:
PMID:  9540763     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Prolymphocytic leukemia (PLL) is a rare lymphoproliferative disorder that takes a rapidly progressive course and where therapeutic interventions are often unsuccessful. In this context, the new purine analogs may be a promising option. We report two cases of PLL treated with cladribine. The first patient had been resistant to polychemotherapy (COP) but responded well to two courses of 2-CdA. He achieved a partial remission, which he maintained for 15 months. The second patient had very advanced disease but obtained a partial response after three courses of 2-CdA, given as a first-line therapy in an ambulatory setting. These results, as well others reported in the literature, permit us to consider 2-CdA as a highly promising therapeutic option for PLL.
Authors:
I Lorand-Metze; G B Oliveira; F J Aranha
Related Documents :
18452673 - Nocardia canaliculitis presenting as pouted punctum.
9624533 - A new case of translocation t(6;11)(q21;q23) in a therapy-related acute myeloid leukemi...
10334253 - Urbanisation of yellow fever in santa cruz, bolivia.
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of hematology     Volume:  76     ISSN:  0939-5555     ISO Abbreviation:  Ann. Hematol.     Publication Date:  1998 Feb 
Date Detail:
Created Date:  1998-04-23     Completed Date:  1998-04-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9107334     Medline TA:  Ann Hematol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  85-6     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Faculty of Medicine, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antineoplastic Agents / therapeutic use*
Cladribine / therapeutic use*
Humans
Leukemia, Prolymphocytic / drug therapy*
Male
Remission Induction
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 4291-63-8/Cladribine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Low-grade MALT lymphoma involving multiple mucosal sites and bone marrow.
Next Document:  Ticlopidine-associated aplastic anemia. A case report and review of literature.